他汀类药物在慢性阻塞性肺疾病稳定期患者中的作用

Efficacy of statin in treatment of patients with chronic obstructive pulmonary disease at stable stage

目的:探讨他汀类药物在慢性阻塞性肺疾病稳定期患者治疗中的作用。方法:83例慢性阻塞性肺疾病稳定期患者随机分为治疗组(41例)和对照组(42例),对照组按诊疗常规予以治疗,治疗组在常规治疗基础上加用瑞舒伐他汀钙片20 mg/d,观察两组治疗前、治疗后12、24、48周时血清CRP水平、肺功能[第1秒钟用力呼气容积(FEV1)、FEV1占预计值百分比(FVC%pred)及COPD评估测试问卷(CAT)变化。结果:在12周时,两组患者血清CRP水平、FEV1、FVC%pred及CAT评分较治疗前有所改善;两组间比较,血清CRP水平及CAT评分差异有统计学意义(P<0.05),FEV1、FVC%pred差异无统计学意义(P>0.05)。24、48周时,两组血清CRP水平、FEV1、FVC%pred及CAT评分较治疗前都有所改善,两组间比较差异均有统计学意义(P<0.05)。结论:他汀类药物可以减轻COPD患者炎症反应,改善肺功能及提高生活质量。

Objective To explore the therapeutic effects of statin in patients with chronic obstructive pulmonary disease （COPD） in stable period. Methods 83 patients with COPD in stable period were recruited and randomly divided into two groups, treatment group （n = 41） and control group （n = 42）.The control group received conventional routine therapy, and treatment group was given rosuvastatin calcium 20 mg once per day on the basis of routine treatment. The levels of sera C-reactive protein （CRP）, pulmonary function （FEV1, FEVl%pred）, and COPD assessment test （CAT） were observed at the time points of 0 week and 12th week, 24th week and 48th week were compared between two groups. Results At 12th week after the treatment, sera CRP levels, FEV1, FEVl%pred and CAT scores in either control group or treatment group showed some extent of improvements as compared to those at the time point of 0 week, and there was statistical difference of sera CRP levels and CAT scores between two groups （P 〈 0.05）. There was no statistical difference of FEV1, FEVl%pred between two groups （P 〉 0.05） .24th week and 48th week after the treatment; sera CRP levels, FEV, FEV1%pred and CAT scores in two groups all significantly improved and were statistical different between two groups （P 〈 0.05）. Conclusion Statin can alleviate inflammatory reaction, improve pulmonary function and life quality of patients with COPD.